ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
2seventy bio Inc

2seventy bio Inc (TSVT)

4.15
0.30
(7.79%)
Closed July 11 4:00PM
4.1516
0.0016
(0.04%)
After Hours: 6:56PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
4.1516
Bid
4.15
Ask
4.25
Volume
1,742,149
3.75 Day's Range 4.37
1.535 52 Week Range 11.29
Market Cap
Previous Close
3.85
Open
3.87
Last Trade
1
@
4.24
Last Trade Time
Financial Volume
$ 7,069,596
VWAP
4.058
Average Volume (3m)
565,513
Shares Outstanding
51,405,419
Dividend Yield
-
PE Ratio
-0.98
Earnings Per Share (EPS)
-4.23
Revenue
100.39M
Net Profit
-217.57M

About 2seventy bio Inc

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. 2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
2seventy bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TSVT. The last closing price for 2seventy bio was $3.85. Over the last year, 2seventy bio shares have traded in a share price range of $ 1.535 to $ 11.29.

2seventy bio currently has 51,405,419 shares outstanding. The market capitalization of 2seventy bio is $197.91 million. 2seventy bio has a price to earnings ratio (PE ratio) of -0.98.

TSVT Latest News

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

- Divestiture Supports Company Focus on Development and Commercialization of Abecma - 2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by...

2seventy bio to Participate in Upcoming Investor Conferences

2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation Summit:...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.19164.838383838383.964.373.754706123.92252451CS
4-0.0484-1.152380952384.24.373.544840623.84956708CS
12-0.8584-17.13373253495.015.12993.445655134.26970654CS
260.18164.574307304793.976.42.89510145534.70632611CS
52-7.0084-62.799283154111.1611.291.53513604654.22360913CS
156-21.9784-84.111748947626.1344.341.5358686518.47447756CS
260-21.9784-84.111748947626.1344.341.5358686518.47447756CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LCFYLocafy Ltd
$ 6.10
(162.92%)
46.08M
KZIAKazia Therapeutics Ltd
$ 1.24
(85.57%)
226.74M
CYNCYNGN Inc
$ 7.20
(81.82%)
18.27M
NEXINexImmune Inc
$ 3.84
(66.23%)
34.48M
BDRXBiodexa Pharmaceuticals PLC
$ 1.08
(51.88%)
63.56M
CETUUCetus Capital Acquisition Corporation
$ 7.00
(-29.72%)
1.42k
TRIBTrinity Biotech PLC
$ 2.046
(-28.96%)
81.97k
CINGCingulate Inc
$ 0.4845
(-25.23%)
1.38M
IVPInspire Veterinary Partners Inc
$ 5.5842
(-24.54%)
2.69M
SLRXSalarius Pharmaceuticals Inc
$ 2.12
(-22.70%)
2.03M
NVDANVIDIA Corporation
$ 127.40
(-5.57%)
374.79M
MAXNMaxeon Solar Technologies Ltd
$ 0.24
(13.85%)
355.51M
KZIAKazia Therapeutics Ltd
$ 1.24
(85.57%)
226.74M
TSLATesla Inc
$ 241.03
(-8.44%)
221.69M
SQQQProShares UltraPro Short QQQ
$ 7.63
(6.42%)
183.23M

TSVT Discussion

View Posts
Monksdream Monksdream 2 months ago
TSVT under $5
👍️0
Invest-in-America Invest-in-America 4 months ago
TSVT: Big (Post-M) news for this Firm & partner Bristol Myers.

"Bristol Myers, 2seventy Bios Cancer Treatment Wins FDA Committee Approval
7:04 PM ET 3/15/24 | Dow Jones
By Ben Glickman Bristol Myers Squibb and 2seventy Bio's cancer treatment showed a favorable risk-benefit profile in certain populations, according to Food and Drug Administration committee. The Oncologic Drugs Advisory Committee voted 8-3 that Abecma, a gene therapy, had a favorable profile in the treatment of the blood cancer multiple myeloma, specifically in the triple-class exposed relapsed or refractory forms of the cancer, the companies said on Friday. Bristol Myers Squibb and 2seventy said the recommendation would be considered by the FDA in its review of their supplemental Biologics License Application. The FDA hasn't assigned a new target action date for reviewing that application, the companies said. Abecma was recently approved in Japan and Switzerland for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. Write to Ben Glickman at ben.glickman@wsj.com > Dow Jones Newswires March 15, 2024 19:04 ET (23:04 GMT)"
👍️0
Monksdream Monksdream 4 months ago
TSVT 10Q due March 5
👍️0
molee molee 5 months ago
$TSVT > A bit of "short covering" going on now ... How high ???
👍️0
Monksdream Monksdream 7 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👎️ 1 💩 1 🤡 1
johnhancoque johnhancoque 8 months ago
2 seventy will be auctioned off in Bankruptcy court within a year. Cash on hand is 12 months or less.
👍️0
molee molee 8 months ago
C'mon man . What the heck . $2.00 now ? Really ?
👍️0

Your Recent History

Delayed Upgrade Clock